The Europe PEGylated Proteins Market should witness market growth of 10.9% CAGR during the forecast period (2022-2028).
The main factors driving the growth are driving the demand for protein-based treatments, along with a boost in research activities for the creation of novel therapeutics and the benefits of PEGylated therapeutic proteins. Other important drivers include the rising incidence of degenerative & chronic diseases such as cancer, rheumatoid arthritis, andkidney disease.
The use of protein-based treatments has grown as a result of advancements in molecular biology engineering and biotechnology. In recent years, it has become quite apparent that there is an ever-increasing demand for recombinant proteins, including enzymes,hormones, growth factors, and monoclonal antibodies, among others.
Due to the therapeutic benefits of specificity and enhanced activity, biologics are now widely available and well-known among the affected community. For instance, the French biotechnology company LFB (Laboratoire Francais du Fractionnement et des Biotechnologies) received approval from the American FDA in April 2020 for a novel treatment for hemophilia.
In Europe, diabetes is growing more prevalent among individuals of all ages as a result of rising overweight and obesity rates, poor diets, and lack of physical activity. According to the World Health Organization, kidney failure accounts for 10 to 20% of cases of death for diabetics and accounts for 50% of deaths from cardiovascular disease (mostly heart disease and stroke). Approximately 60 million people in the European Region - 10.3% of males and 9.6% of women over 25 - have diabetes.
The Germany market dominated the Europe PEGylated Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $137.6 million by 2028. The UK market is experiencing CAGR of 9.9% during (2022-2028). Additionally, The France market would display a CAGR of 11.7% during (2022-2028).
Based on Product & Services, the market is segmented into Consumables and Services. Based on Type, the market is segmented into Colony-stimulating Factor, Interferons, Recombinant Factor VII, Erythropoietin and Others. Based on End-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs) and Academic & Research Institutes. Based on Application, the market is segmented into Cancer, Autoimmune Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Merck Millipore (Merck KGaA), Thermo Fisher Scientific, Inc., NOF Corporation, JenKem Technology Co. Ltd., Creative PEGworks, Celares GmbH, Quanta BioDesign, Ltd., Biomatrik, Inc., Iris Biotech GmbH, and Laysan Bio, Inc.
The main factors driving the growth are driving the demand for protein-based treatments, along with a boost in research activities for the creation of novel therapeutics and the benefits of PEGylated therapeutic proteins. Other important drivers include the rising incidence of degenerative & chronic diseases such as cancer, rheumatoid arthritis, andkidney disease.
The use of protein-based treatments has grown as a result of advancements in molecular biology engineering and biotechnology. In recent years, it has become quite apparent that there is an ever-increasing demand for recombinant proteins, including enzymes,hormones, growth factors, and monoclonal antibodies, among others.
Due to the therapeutic benefits of specificity and enhanced activity, biologics are now widely available and well-known among the affected community. For instance, the French biotechnology company LFB (Laboratoire Francais du Fractionnement et des Biotechnologies) received approval from the American FDA in April 2020 for a novel treatment for hemophilia.
In Europe, diabetes is growing more prevalent among individuals of all ages as a result of rising overweight and obesity rates, poor diets, and lack of physical activity. According to the World Health Organization, kidney failure accounts for 10 to 20% of cases of death for diabetics and accounts for 50% of deaths from cardiovascular disease (mostly heart disease and stroke). Approximately 60 million people in the European Region - 10.3% of males and 9.6% of women over 25 - have diabetes.
The Germany market dominated the Europe PEGylated Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $137.6 million by 2028. The UK market is experiencing CAGR of 9.9% during (2022-2028). Additionally, The France market would display a CAGR of 11.7% during (2022-2028).
Based on Product & Services, the market is segmented into Consumables and Services. Based on Type, the market is segmented into Colony-stimulating Factor, Interferons, Recombinant Factor VII, Erythropoietin and Others. Based on End-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs) and Academic & Research Institutes. Based on Application, the market is segmented into Cancer, Autoimmune Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Merck Millipore (Merck KGaA), Thermo Fisher Scientific, Inc., NOF Corporation, JenKem Technology Co. Ltd., Creative PEGworks, Celares GmbH, Quanta BioDesign, Ltd., Biomatrik, Inc., Iris Biotech GmbH, and Laysan Bio, Inc.
Scope of the Study
By Product & Services
- Consumables
- Services
By Type
- Colony-stimulating Factor
- Interferons
- Recombinant Factor VII
- Erythropoietin
- Others
By End-user
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
By Application
- Cancer
- Autoimmune Diseases
- Hepatitis
- Multiple Sclerosis
- Hemophilia
- Gastrointestinal Disorders
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Merck Millipore (Merck KGaA)
- Thermo Fisher Scientific, Inc.
- NOF Corporation
- JenKem Technology Co. Ltd.
- Creative PEGworks
- Celares GmbH
- Quanta BioDesign, Ltd.
- Biomatrik, Inc.
- Iris Biotech GmbH
- Laysan Bio, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Europe PEGylated Proteins Market by Product & Services
Chapter 5. Europe PEGylated Proteins Market by Type
Chapter 6. Europe PEGylated Proteins Market by End-user
Chapter 7. Europe PEGylated Proteins Market by Application
Chapter 8. Europe PEGylated Proteins Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Merck Millipore (Merck KGaA)
- Thermo Fisher Scientific, Inc.
- NOF Corporation
- JenKem Technology Co. Ltd.
- Creative PEGworks
- Celares GmbH
- Quanta BioDesign, Ltd.
- Biomatrik, Inc.
- Iris Biotech GmbH
- Laysan Bio, Inc.
Methodology
LOADING...
